Exploring Genus And 2 Other High Growth Tech Stocks In The UK

Despite recent declines in the FTSE 100 and FTSE 250 indices, driven by weak trade data from China and falling commodity prices, the UK market remains a fertile ground for high-growth technology stocks. In this article, we explore Genus and two other promising tech companies that are navigating these challenging conditions with innovative solutions and robust growth strategies.

Top 10 High Growth Tech Companies In The United Kingdom

Name	Revenue Growth	Earnings Growth	Growth Rating
STV Group	13.15%	46.78%	★★★★★☆
Gaming Realms	11.57%	22.07%	★★★★★☆
YouGov	14.29%	29.79%	★★★★★☆
Altitude Group	23.46%	27.56%	★★★★★☆
Facilities by ADF	52.00%	144.70%	★★★★★☆
Redcentric	4.89%	63.79%	★★★★★☆
Windar Photonics	63.60%	126.92%	★★★★★☆
Beeks Financial Cloud Group	24.63%	57.95%	★★★★★☆
Oxford Biomedica	20.98%	106.13%	★★★★★☆
Vinanz	113.60%	125.86%	★★★★★☆

Click here to see the full list of 47 stocks from our UK High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Genus (LSE:GNS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia and has a market cap of £1.32 billion.

Operations: Genus plc generates revenue primarily through its two main segments: Genus ABS, which contributed £314.90 million, and Genus PIC, which brought in £352.50 million. The company operates globally across various regions including North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia.

Genus plc, navigating a challenging fiscal year with sales dipping to £668.8 million from £689.7 million, still projects robust earnings growth at 39.4% annually, outpacing the UK market's 14.3%. Despite a significant one-off loss of £47.4 million affecting its recent financials and reducing net income to £7.9 million from last year's £33.3 million, the company maintains optimism with an expected revenue increase of 4.1% per year—slightly ahead of the market average of 3.8%. This resilience in forecasted growth amidst current adversities highlights Genus's potential in leveraging R&D for recovery and innovation in biotech, aligning with industry advancements despite current setbacks.

• Click here to discover the nuances of Genus with our detailed analytical health report.

• Gain insights into Genus' historical performance by reviewing our past performance report.

NCC Group (LSE:NCC)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: NCC Group plc operates in the cyber and software resilience industry across the United Kingdom, Asia-Pacific, North America, and Europe, with a market cap of £542.72 million.

Operations: NCC Group plc generates revenue primarily from Cyber Security (£258.50 million) and Escode (£65.90 million). The company operates across multiple regions including the UK, Asia-Pacific, North America, and Europe.

NCC Group, recently added to the FTSE 250 and FTSE 350 indices, demonstrates a promising trajectory despite current unprofitability. With an expected revenue growth of 4.5% per year—surpassing the UK market average of 3.8%—and a projected earnings increase of 87.4%, NCC is poised for significant financial recovery. This growth is underpinned by strategic expansions like the SEK 450 million water infrastructure project in Sweden, enhancing municipal services and environmental compliance. Moreover, with R&D expenses strategically allocated to foster innovation and efficiency within its cybersecurity solutions, NCC aligns well with industry demands for enhanced digital security measures, setting a robust foundation for future profitability and market competitiveness.

• Dive into the specifics of NCC Group here with our thorough health report.

• Evaluate NCC Group's historical performance by accessing our past performance report.

Oxford Biomedica (LSE:OXB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide and has a market cap of £401.88 million.

Operations: Oxford Biomedica generates revenue primarily through its Platform segment, which contributed £97.24 million. The company operates as a contract development and manufacturing organization, focusing on delivering therapies globally.

Oxford Biomedica, despite its current unprofitability, is on a robust upward trajectory with revenue forecasted to grow at 21% annually, significantly outpacing the UK market average of 3.8%. This growth is bolstered by a substantial projected increase in earnings of 106.13% per year over the next three years. The company's commitment to R&D is evident as it strategically channels funds into this area, ensuring innovation remains at the forefront of its operations amid evolving biotech landscapes. Recent executive changes and reaffirmed financial guidance further underscore Oxford Biomedica's proactive approach in strengthening its market position and enhancing shareholder value through focused leadership and clear strategic directives.

• Get an in-depth perspective on Oxford Biomedica's performance by reading our health report here.

• Learn about Oxford Biomedica's historical performance.

Taking Advantage

• Embark on your investment journey to our 47 UK High Growth Tech and AI Stocks selection here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com